RedHill Biopharma Files 6-K on Talicia® Performance

TL;DR

RHBP files 6-K on Talicia® – key drug update incoming.

AI Summary

RedHill Biopharma Ltd. filed a Form 6-K on September 9, 2024, to report on the performance of its drug Talicia®. The filing indicates that Talicia® is a key product for the company, and the report likely contains updates on its sales, clinical trials, or regulatory status.

Why It Matters

This filing provides investors with crucial updates on RedHill Biopharma's flagship product, Talicia®, which is essential for understanding the company's current financial health and future prospects.

Risk Assessment

Risk Level: medium — Form 6-K filings are typically for routine updates and do not inherently signal high risk, but the specific content regarding Talicia® could reveal significant developments.

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• Talicia® (product) — Key drug product

FAQ

Filing Documents

• zk2432010.htm (6-K) — 49KB
• image00001.jpg (GRAPHIC) — 491KB
• 0001178913-24-003010.txt ( ) — 726KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: September 9, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill's Talicia Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines First new American College of Gastroenterology (ACG) Clinical Guideline 1 for H. pylori infection since Talicia's approval lists Talicia as an empirically prescribed first-line option -- Talicia's convenient all-in-one three times daily (TID) formulation offers a simplified patient experience, supporting high rates of eradication without needing prior resistance testing -- Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists 2 for H. pylori infection, which affects approximately 35% of the U.S. adult population 3 -- Worldwide, around 66% of the population has H. pylori infection 4 , which is classified by the World Health Organization (WHO) as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer 5 and a major risk factor for peptic ulcer disease 6 RALEIGH, N.C. and TEL-AVIV, Israel, September 9, 2024, RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the placement of low-dose rifabutin-triple therapy, Talicia, as an empirically-prescribed first-line option for the treatment of Helicobacter pylori ( H. pylori ) infection in the newly published American College of Gastroenterology (ACG) Clinical Guideline: Treatment of H. pylori Infection, previously updated in 2017. "The ACG Clinical Guideline is clear that clarithromycin-based triple therapy is no longer a reliable first-line option for the treatment of H. pylori infection, unless prior resi

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the potential effects of Talicia in the treatment of Helicobacter pylori infection. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-10

View Full Filing

View this 6-K filing on SEC EDGAR